Early-Stage trial halted for aggressive blood cancer treatment
NCT ID NCT05626322
Summary
This early-stage study tested a combination of three medicines for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma that had returned or stopped responding to prior treatment. The trial was for patients who could not receive a stem cell transplant or certain cell therapies. The main goal was to find a safe and effective dose for the new drug, maplirpacept, when given with two other approved lymphoma drugs. The study was terminated after enrolling only 6 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dong-A University Hospital
Busan, Pusan-kwangyǒkshi, 49201, South Korea
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809, United States
-
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Yamagata University Hospital
Yamagata, 990-9585, Japan
Conditions
Explore the condition pages connected to this study.